Lancet Oncol:20-39岁青年人群肿瘤发病及死亡率研究

2017-10-30 zhangfan MedSci原创

研究发现,全球20-39岁青年人群肿瘤发病及死亡率随年龄、性别、发展水平和地理区域存在极大差异。有目的的监测,预防和治疗都将有助于减少不发达地区的肿瘤负担

近日研究人员对20-39岁青年人群的肿瘤发病及死亡率进行了研究,考察不同年龄、性别、经济发展水平和地理区域的差异。

本次基于人群的研究的目的是量化全世界年轻人群的癌症负担。20-39岁人群经过青春期后,身体机能逐步健全且鲜有慢性健疾病、荷尔蒙衰退、免疫反应恶化或器官功能障碍的影响。研究考察了2012年184各国家,20-39岁人群的27种主要肿瘤发病及死亡年龄标准化发病率(ASR),同时采用人类发展指数(HDI; 低、中等、高、极高)评估研究结果。

2012年,全球范围内,20-39岁人群共发生975396例新发肿瘤以及358392例肿瘤相关死亡。每十万人中,肿瘤新发ASR为43.3,死亡ASR为15.9。青年女性肿瘤负担高于男性,最常见的女性新发肿瘤为:乳腺癌、宫颈癌、甲状腺癌、白血病和结肠癌,死亡类型为乳腺癌,肝癌,白血病和宫颈癌。肿瘤发病率随地区发展水平和地理区域变化很大;欠发达地区感染相关癌症负担更大。HDI指数高地区与低地区相比,肿瘤发病风险差异显著(ASR 64.5 vs 46.2),死亡率低HDI地区是发达地区的3倍(ASR 25.4 vs 9.2)。

研究发现,全球20-39岁青年人群肿瘤发病及死亡率随年龄、性别、发展水平和地理区域存在极大差异。有目的的监测,预防和治疗都将有助于减少不发达地区的肿瘤负担。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829290, encodeId=3d28182929012, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 26 06:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916799, encodeId=584d1916e999f, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Thu Mar 08 12:11:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865170, encodeId=c88118651e051, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 01 13:11:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257618, encodeId=e97325e6181b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 31 23:43:57 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257185, encodeId=757825e18501, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Mon Oct 30 09:40:23 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2017-11-26 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829290, encodeId=3d28182929012, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 26 06:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916799, encodeId=584d1916e999f, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Thu Mar 08 12:11:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865170, encodeId=c88118651e051, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 01 13:11:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257618, encodeId=e97325e6181b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 31 23:43:57 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257185, encodeId=757825e18501, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Mon Oct 30 09:40:23 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2018-03-08 zll0625
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829290, encodeId=3d28182929012, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 26 06:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916799, encodeId=584d1916e999f, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Thu Mar 08 12:11:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865170, encodeId=c88118651e051, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 01 13:11:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257618, encodeId=e97325e6181b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 31 23:43:57 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257185, encodeId=757825e18501, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Mon Oct 30 09:40:23 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2017-11-01 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829290, encodeId=3d28182929012, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 26 06:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916799, encodeId=584d1916e999f, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Thu Mar 08 12:11:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865170, encodeId=c88118651e051, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 01 13:11:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257618, encodeId=e97325e6181b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 31 23:43:57 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257185, encodeId=757825e18501, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Mon Oct 30 09:40:23 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2017-10-31 1e0ece0dm09(暂无匿称)

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829290, encodeId=3d28182929012, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 26 06:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916799, encodeId=584d1916e999f, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Thu Mar 08 12:11:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865170, encodeId=c88118651e051, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 01 13:11:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257618, encodeId=e97325e6181b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 31 23:43:57 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257185, encodeId=757825e18501, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Mon Oct 30 09:40:23 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2017-10-30 186****0580(小山羊)

    学习了谢谢了

    0

相关资讯

肿瘤常见并发症——上腔静脉综合征的临床处理

什么是上腔静脉综合征?上腔静脉综合征(superior vein cave syndrome, SVCS)是由于上腔静脉回流到右心房的血流部分或完全受阻而导致的一系列临床综合征。根据起病的缓急、梗阻的部位、阻塞的程度及是否建立有效的侧枝循环等情况表现为肿瘤急症或亚急症。解剖位置及病理生理上腔静脉位于右侧第一胸肋关节后方,由左右头臂静脉汇合而成,注入右心房。上腔静脉负责收集头颈、上肢、胸壁及部分胸腔

疑似肾囊实性肿瘤 实则……

63岁女性,体检发现右肾实性占位3个月。下一步该进行哪些检查?治疗过程中有哪些注意事项?

CLIN CANCER RES:Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果

Trebananib是抑制血管生成素1和2的一线抗血管生成抗体。CLIN CANCER RES近期发表了一篇文章,报道了Trebananib用于治疗儿童肿瘤的Ⅰ期临床试验结果,包括剂量限制毒性(DLT)、推荐Ⅱ期试验剂量(RP2D)和药代动力学等。

Nat Commun:大数据揭开肿瘤向周围传播扩散的“秘密”!

加州旧金山的研究人员结合起源似乎不兼容的数据,分析了八种最常见癌症中肿瘤相邻组织中的分子特征,表明它们都使用相同的机制来改造正常组织并传播。

生死一刻,医患并肩战斗!

医和患到底是什么关系?透过这起病例,我相信无论在朱玉萍医生的心中,还是在患者一家人的心中,经过生死洗礼之后都会有说不出的美好和美妙。而这美好和美妙的背后是爱。生死面前,最难的往往不是技术。唯有爱,才能让医患走得更远!唯有爱,才能让医患共赢!

著名肿瘤专家华益慰的遗言:真正让自己康复的**不是药物

“我从前做了那么多手术,但对术后病人的痛苦体会不深。没想到情况这么严重,没想到病人会这么痛苦……”临终前,名医华益慰留下了无比沉痛的话语。这也是他留给世人最后的警示。